Camoteskimab for Eczema
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to test the effectiveness and safety of a new treatment called camoteskimab for individuals with moderate to severe eczema, a condition that causes itchy, inflamed skin. Participants will receive either one of two different doses of camoteskimab or a placebo (a dummy treatment) to compare results. It suits adults who have had eczema for at least a year, experience significant skin involvement, and have not found success with topical treatments. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.
Will I have to stop taking my current medications?
The trial protocol does not specify if you must stop taking your current medications. However, if you are using certain systemic therapies for eczema, you may need to stop them before joining the trial.
Is there any evidence suggesting that camoteskimab is likely to be safe for humans?
Research has shown that camoteskimab was safe in earlier studies. Patients who took camoteskimab experienced significant improvement in their eczema symptoms, indicating the treatment's effectiveness. These studies did not identify any major side effects associated with the treatment. Camoteskimab is currently in a Phase 2 trial, which means it has already passed initial safety tests. This phase examines its safety and effectiveness in a larger group of patients. Overall, the treatment appears well-tolerated, but ongoing studies will provide more detailed safety information.12345
Why do researchers think this study treatment might be promising?
Researchers are excited about Camoteskimab for eczema because it offers a potentially new way to tackle the condition. Most current treatments, like topical steroids and calcineurin inhibitors, focus on reducing inflammation and suppressing the immune response. However, Camoteskimab is thought to work by specifically targeting and modulating certain pathways of the immune system that are involved in eczema, possibly leading to more precise treatment. This precision might mean fewer side effects and better outcomes for patients. Additionally, the introduction of Camoteskimab could provide an option for those who have not responded well to existing treatments.
What evidence suggests that camoteskimab might be an effective treatment for eczema?
Research has shown that camoteskimab holds promise for treating eczema. Studies found that patients taking camoteskimab experienced noticeable improvement in eczema symptoms and affected skin areas. The treatment was well tolerated, with no serious side effects linked to the medication. This trial will evaluate different doses of camoteskimab to determine its effectiveness and safety, suggesting that camoteskimab could be an effective option for people with moderate to severe eczema.13467
Are You a Good Fit for This Trial?
Adults with moderate to severe atopic dermatitis (a type of eczema) can join this study. Participants must meet certain health standards, which are not specified here.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment (Blinded Period)
Participants are randomized to receive either camoteskimab dose 1, camoteskimab dose 2, or placebo
Extension Period (Open-label)
All participants receive camoteskimab
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Camoteskimab
Find a Clinic Near You
Who Is Running the Clinical Trial?
Apollo Therapeutics Ltd
Lead Sponsor